AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29850509 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight supported treadmill training with visual biofeedback (BB group)
Number of subjects: 30
Study 29850509 — intervention group
Group type: COMPARATOR
Intervention: Body weight supported treadmill training without visual biofeedback (Control group)
Number of subjects: 30
Study 27381507 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat biscuits with 4% inulin (OBIN)
Number of subjects: 11
Study 27381507 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat biscuits (OB)
Number of subjects: 11
Study 27381507 — intervention group
Group type: COMPARATOR
Intervention: Glucose solution (reference food)
Number of subjects: 11
Study 24129610 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized diet plan with close follow-up by a dietician
Number of subjects: 154
Study 24129610 — intervention group
Group type: COMPARATOR
Intervention: Standard dietary care via a brochure on healthy eating during pregnancy
Number of subjects: 154
Study 22972220 — intervention group
Group type: EXPERIMENTAL
Intervention: One session spouse-support enhancement childbirth education
Number of subjects: 61
Study 22972220 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 61
Study 19078903 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation (MV)
Number of subjects: 30
Study 19078903 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous breathing after extubation
Number of subjects: 30
Study 17373639 — intervention group
Group type: EXPERIMENTAL
Intervention: Pump device delivering lispro
Number of subjects: 17
Study 17373639 — intervention group
Group type: EXPERIMENTAL
Intervention: Three daily injections of lispro plus NPH
Number of subjects: 17
Study 15800765 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F FDG PET after neoadjuvant treatment
Number of subjects: 32
Study 15800765 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete metabolic remission (detected by PET)
Number of subjects: 32
Study 15800765 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete metabolic remission (detected by PET)
Number of subjects: 32
Study 15800765 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic regression grade III/IIb
Number of subjects: 32
Study 15800765 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic regression grade IIa/I
Number of subjects: 32
Study 11929760 — intervention group
Group type: EXPERIMENTAL
Intervention: E coli-asparaginase
Number of subjects: 700
Study 11929760 — intervention group
Group type: COMPARATOR
Intervention: Erwinia-asparaginase
Number of subjects: 700
Study 9808397 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyriax's concept of the capsular pattern
Number of subjects: 200
Study 8594004 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydration trial (DE) with 0.2 liter of fluid leading to dehydration of 4.9 +/- 0.2% body weight
Number of subjects: 7
Study 8594004 — intervention group
Group type: COMPARATOR
Intervention: Euhydration trial (EU) with 3.6 +/- 0.4 liter of fluid replacing 95% of fluid losses
Number of subjects: 7
Study 8594004 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydration trial (DE)
Number of subjects: 7
Study 2775617 — intervention group
Group type: EXPERIMENTAL
Intervention: L-648,051 12.0 mg
Number of subjects: 0
Study 2775617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 778880 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa with carbidopa
Number of subjects: 50
Study 778880 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergic drugs and/or amantadine
Number of subjects: 50
Study 778880 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 50
Study 31068223 — intervention group
Group type: EXPERIMENTAL
Intervention: Short stretch compression bandaging
Number of subjects: 2600
Study 31068223 — intervention group
Group type: COMPARATOR
Intervention: Standard wool and crepe bandaging
Number of subjects: 2600
Study 28238489 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic removal of endometriosis
Number of subjects: 0
Study 28238489 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic removal of endometriosis
Number of subjects: 0
Study 28238489 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (robotic and laparoscopic)
Number of subjects: 0
Study 25426808 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz
Number of subjects: 389
Study 25426808 — intervention group
Group type: COMPARATOR
Intervention: lopinavir/ritonavir
Number of subjects: 389
Study 23300211 — intervention group
Group type: EXPERIMENTAL
Intervention: Active PAS
Number of subjects: 0
Study 23300211 — intervention group
Group type: COMPARATOR
Intervention: Sham PAS
Number of subjects: 0
Study 21200079 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural activation
Number of subjects: 47
Study 21200079 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 47
Study 18633001 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele‐VR group (virtual reality therapy at home)
Number of subjects: 10
Study 18633001 — intervention group
Group type: COMPARATOR
Intervention: VR group (virtual reality therapy in hospital)
Number of subjects: 10
Study 18633001 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele‐VR group
Number of subjects: 10
Study 15928959 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO 160/120
Number of subjects: 257
Study 15928959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study 12202326 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate palliative thoracic radiotherapy
Number of subjects: 230
Study 12202326 — intervention group
Group type: COMPARATOR
Intervention: Delayed palliative thoracic radiotherapy
Number of subjects: 230
Study 10333382 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 11
Study 10333382 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 11
Study 10333382 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine with antagonist
Number of subjects: 11
Study 10333382 — intervention group
Group type: EXPERIMENTAL
Intervention: Gpp(NH)p
Number of subjects: 11
Study 8611783 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 204
Study 8611783 — intervention group
Group type: COMPARATOR
Intervention: Hysteroscopic surgery (transcervical resection or laser ablation)
Number of subjects: 204
Study 8611783 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 204
Study 2007319 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg caffeine, t.i.d., administered orally during one of the 8-day periods
Number of subjects: 8
Study 2007319 — intervention group
Group type: COMPARATOR
Intervention: 1200 mg anhydrous theophylline administered as a two-stage infusion during 24 hours
Number of subjects: 8
Study 2007319 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine administration
Number of subjects: 8
Study 6684153 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein isolate (SPI)
Number of subjects: 21
Study 6684153 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish protein (cod fish)
Number of subjects: 21
Study 6684153 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed protein (50:50 mixture of SPI and fish protein)
Number of subjects: 21
Study 6684153 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein isolate (SPI) relative to fish protein
Number of subjects: 21
Study 31431412 — intervention group
Group type: EXPERIMENTAL
Intervention: HBsAg/CpG 1018 (HEPLISAV-B®)
Number of subjects: 480
Study 28244291 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin (10 mg/m²/week) as part of a reinduction regimen including prednisolone, vincristine, and L-asparaginase.
Number of subjects: 44
Study 28244291 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin (10 mg/m²/week) as part of a reinduction regimen.
Number of subjects: 44
Study 24659208 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined soy foods group (soy protein and whole soy)
Number of subjects: 450
Study 24659208 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (milk placebo)
Number of subjects: 450
Study 24659208 — intervention group
Group type: COMPARATOR
Intervention: Combined isoflavone group (isoflavone and daidzein)
Number of subjects: 450
Study 24405687 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC transfusion
Number of subjects: 521
Study 24405687 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention
Number of subjects: 521
Study 22943372 — intervention group
Group type: EXPERIMENTAL
Intervention: Determinants of LBW
Number of subjects: 14040
Study 22943372 — intervention group
Group type: EXPERIMENTAL
Intervention: Determinants of SGA
Number of subjects: 14040
Study 22943372 — intervention group
Group type: EXPERIMENTAL
Intervention: Determinants of preterm birth
Number of subjects: 14040
Study 22943372 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventable determinants
Number of subjects: 14040
Study 19542853 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pressure pneumoperitoneum (8 mm Hg)
Number of subjects: 26
Study 19542853 — intervention group
Group type: COMPARATOR
Intervention: High pressure pneumoperitoneum (12 mm Hg)
Number of subjects: 26
Study 17692448 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (458.3 mg/day)
Number of subjects: 87
Study 17692448 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (4.2 mg/day)
Number of subjects: 87
Study 17692448 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 87
Study 17692448 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 87
Study 15505596 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (1200 mg/d)
Number of subjects: 27
Study 15505596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 11120490 — intervention group
Group type: EXPERIMENTAL
Intervention: Validated patient information leaflet (PIL) on oral cancer
Number of subjects: 800
Study 9888161 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle biopsy examination
Number of subjects: 57
Study 9888161 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunolabelling for desmin
Number of subjects: 57
Study 9888161 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunolabelling for dystrophin, actin, and myosin heavy chains
Number of subjects: 57
Study 9888161 — intervention group
Group type: EXPERIMENTAL
Intervention: Myosin ATPase activity
Number of subjects: 57
Study 9888161 — intervention group
Group type: EXPERIMENTAL
Intervention: Electron microscopy
Number of subjects: 57
Study 9888161 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunolabelling for cathepsin B, lysozyme, and ubiquitin
Number of subjects: 57
Study 9888161 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunolabelling for heat shock protein 72
Number of subjects: 57
Study 9888161 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE II scores
Number of subjects: 57
Study 7625194 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (378 mg +/‐ 76 mg/day)
Number of subjects: 59
Study 7625194 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (36 mg +/‐ 8 mg/day)
Number of subjects: 59
Study 7625194 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drug groups
Number of subjects: 59
Study 2684489 — intervention group
Group type: EXPERIMENTAL
Intervention: Health‐Net (treatment group)
Number of subjects: 1003
Study 725 — intervention group
Group type: EXPERIMENTAL
Intervention: psychotherapy with Ro 5‐3350 (TH/Ro)
Number of subjects: 78
Study 725 — intervention group
Group type: COMPARATOR
Intervention: psychotherapy with placebo (TH/P)
Number of subjects: 78
Study 725 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 5‐3350 without psychotherapy (NIH/Ro)
Number of subjects: 78
Study 725 — intervention group
Group type: COMPARATOR
Intervention: placebo without psychotherapy (NTH/P)
Number of subjects: 78
Study 31238370 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive pressure ventilation (PPV)
Number of subjects: 44
Study 31238370 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained inflation (SI)
Number of subjects: 44
Study 28102113 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity RAGT at 70% of HRR
Number of subjects: 34
Study 28102113 — intervention group
Group type: COMPARATOR
Intervention: High-intensity RAGT at RPE of 15
Number of subjects: 34
Study 26939318 — intervention group
Group type: EXPERIMENTAL
Intervention: Fire-needle treatment (once every two days for 30 days, 15 times total)
Number of subjects: 60
Study 26939318 — intervention group
Group type: EXPERIMENTAL
Intervention: Fire-needle treatment
Number of subjects: 60
Study 26939318 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation exercises (five times a week for 4 weeks, 20 times total)
Number of subjects: 60
Study 23112286 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel neonatal resuscitation cart (NRC)
Number of subjects: 15
Study 23112286 — intervention group
Group type: COMPARATOR
Intervention: Generic code cart (GCC)
Number of subjects: 15
Study 21835288 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 318
Study 21835288 — intervention group
Group type: EXPERIMENTAL
Intervention: hsTnI
Number of subjects: 318
Study 21835288 — intervention group
Group type: COMPARATOR
Intervention: cTnT
Number of subjects: 318
Study 21835288 — intervention group
Group type: EXPERIMENTAL
Intervention: Unbound free fatty acids (FFAu)
Number of subjects: 318
Study 21835288 — intervention group
Group type: COMPARATOR
Intervention: cTnT with NT-proBNP
Number of subjects: 318
Study 21835288 — intervention group
Group type: COMPARATOR
Intervention: cTnT with hsTnI
Number of subjects: 318
Study 21835288 — intervention group
Group type: COMPARATOR
Intervention: cTnT with FFAu
Number of subjects: 318
Study 21835288 — intervention group
Group type: EXPERIMENTAL
Intervention: hsTnI with FFAu
Number of subjects: 318
Study 21835288 — intervention group
Group type: EXPERIMENTAL
Intervention: FFAu in serial sampling
Number of subjects: 318
Study 19747247 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylaminolevulinate (MAL) 160 mg/g cream
Number of subjects: 34
Study 19747247 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid (ALA) cream 20%
Number of subjects: 34
Study 16675905 — intervention group
Group type: EXPERIMENTAL
Intervention: Temocapril (1 mg daily)
Number of subjects: 24
Study 16675905 — intervention group
Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 24
Study 15606398 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine micropellets (3 g/day)
Number of subjects: 362
Study 15606398 — intervention group
Group type: COMPARATOR
Intervention: Mesalazine tablets (3 g/day)
Number of subjects: 362
Study 15606398 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (micropellets and tablets)
Number of subjects: 362
Study 11748520 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (2 microg/kg/min infusion)
Number of subjects: 30
Study 11748520 — intervention group
Group type: COMPARATOR
Intervention: Milrinone (50 microg/kg loading dose)
Number of subjects: 30
Study 11748520 — intervention group
Group type: COMPARATOR
Intervention: Combination of nitroglycerin and milrinone
Number of subjects: 30
Study 11748520 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine (administered to increase mean arterial pressure by 20%)
Number of subjects: 30
Study 11748520 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine with milrinone or both drugs combined
Number of subjects: 30
Study 9426799 — intervention group
Group type: EXPERIMENTAL
Intervention: Active smokers
Number of subjects: 0
Study 9426799 — intervention group
Group type: COMPARATOR
Intervention: Abstinent smokers
Number of subjects: 0
Study 9426799 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 0
Study 8491393 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide‐N‐oxide (3 mg orally twice daily)
Number of subjects: 18
Study 8491393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3046883 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine 12.5 mg daily
Number of subjects: 125
Study 3046883 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine 25 mg daily
Number of subjects: 125
Study 3046883 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine 50 mg daily
Number of subjects: 125
Study 3046883 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine 100 mg daily
Number of subjects: 125
Study 3046883 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine 200 mg daily
Number of subjects: 125
Study 3046883 — intervention group
Group type: COMPARATOR
Intervention: Cicletanine 50 mg daily (12 weeks)
Number of subjects: 125
Study 30350153 — intervention group
Group type: EXPERIMENTAL
Intervention: JD (passive simulated jogging device)
Number of subjects: 22
Study 30350153 — intervention group
Group type: COMPARATOR
Intervention: SHAM control
Number of subjects: 22
Study 28471012 — intervention group
Group type: COMPARATOR
Intervention: Transvenous lead placement
Number of subjects: 52
Study 28471012 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicardial lead placement
Number of subjects: 52
Study 25380167 — intervention group
Group type: EXPERIMENTAL
Intervention: Multielectrode renal denervation (RDN)
Number of subjects: 18
Study 25380167 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 24103531 — intervention group
Group type: EXPERIMENTAL
Intervention: Veress needle (VER)
Number of subjects: 595
Study 24103531 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct trocar insertion (DIR)
Number of subjects: 595
Study 24103531 — intervention group
Group type: EXPERIMENTAL
Intervention: Open technique (OP)
Number of subjects: 595
Study 22082432 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure at the Sanyinjiao point
Number of subjects: 86
Study 22082432 — intervention group
Group type: COMPARATOR
Intervention: Sham pressure
Number of subjects: 86
Study 18450322 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus conventional-dose epirubicin (GE)
Number of subjects: 80
Study 18450322 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus cisplatin (GC)
Number of subjects: 80
Study 18450322 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with expression of both ERCC1 and TopoIIalpha
Number of subjects: 80
Study 21617335 — intervention group
Group type: EXPERIMENTAL
Intervention: CDC web-based intervention (screen for life)
Number of subjects: 1224
Study 21617335 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored interactive computer-based intervention
Number of subjects: 1224
Study 21617335 — intervention group
Group type: COMPARATOR
Intervention: Survey-only control group
Number of subjects: 1224
Study 16059842 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized version of the WILDE intelligence test (WIT)
Number of subjects: 0
Study 16059842 — intervention group
Group type: COMPARATOR
Intervention: Paper-and-pencil version of the WILDE intelligence test (WIT)
Number of subjects: 0
Study 11833826 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin ER 40 mg
Number of subjects: 76
Study 11833826 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin IR 40 mg
Number of subjects: 76
Study 11833826 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin ER
Number of subjects: 76
Study 11833826 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin IR
Number of subjects: 76
Study 9437308 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracapsular cataract extraction with aphakic glasses (ICCE‐AG)
Number of subjects: 3400
Study 9437308 — intervention group
Group type: COMPARATOR
Intervention: Extracapsular cataract extraction with posterior chamber intraocular lens (ECCE/PC-IOL)
Number of subjects: 3400
Study 8620672 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton 600mg with food
Number of subjects: 18
Study 8620672 — intervention group
Group type: COMPARATOR
Intervention: Zileuton 600mg without food
Number of subjects: 18
Study 2672652 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg isosorbide dinitrate s.r. (slow release)
Number of subjects: 18
Study 2672652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 892377 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% peptone perfusion at 2 ml per min for 4 hr
Number of subjects: 14
Study 892377 — intervention group
Group type: COMPARATOR
Intervention: 0.2 M NaCl perfusion at 2 ml per min for 4 hr (Control)
Number of subjects: 14
Study 892377 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentagastrin 6 μg/kg subcutaneously
Number of subjects: 14
Study 892377 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal peptone perfusion
Number of subjects: 14
Study 4869880 — intervention group
Group type: EXPERIMENTAL
Intervention: Two new sedatives
Number of subjects: 0
Study 4869880 — intervention group
Group type: COMPARATOR
Intervention: Standard barbiturate
Number of subjects: 0
Study 4869880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 4869880 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 0
Study 31810220 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem solving based psychoeducational group intervention (PE)
Number of subjects: 22
Study 31810220 — intervention group
Group type: COMPARATOR
Intervention: Nonstructured group (NS)
Number of subjects: 22
Study 30496464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethambutol arm
Number of subjects: 1932
Study 30496464 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid arm
Number of subjects: 1932
Study 26695353 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbell hip thrust
Number of subjects: 13
Study 26695353 — intervention group
Group type: COMPARATOR
Intervention: American hip thrust
Number of subjects: 13
Study 26695353 — intervention group
Group type: COMPARATOR
Intervention: Band hip thrust
Number of subjects: 13
Study 25205361 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPD) at a dosage of 0.5 to 0.8 mg/kg/d
Number of subjects: 39
Study 25205361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 22192670 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/d for 3 days before surgery
Number of subjects: 303
Study 22192670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303